Background {#Sec1}
==========

The global tuberculosis (TB) burden continues to be a major public health challenge despite efforts to reduce its impact. Globally in 2016, there were an estimated 10.4 million incident cases of TB, equivalent to 140 cases per 100, 000 population \[[@CR1]\]. Of these incident cases of TB in 2016, an estimated 1.9 million were attributed to undernourishment, 1.0 million to HIV, 0.8 million to smoking, and 0.8 million to diabetes \[[@CR1]\]. In the era of the sustainable development goals, post-2015, the "*End TB Strategy*" targets to reduce TB incidence by 80% by year 2030 \[[@CR2]\]. However, the global epidemiological and demographic transitions pose significant challenge to TB control programs by changing the relative importance of different risk factors for TB \[[@CR3], [@CR4]\].

The global diabetes mellitus (DM) epidemic poses a significant bottleneck to the TB control program \[[@CR3], [@CR4]\]. The International Diabetes Federation (IDF) estimated that, globally in 2013, 382 million adults have diabetes of whom 80% live in low-and middle-income countries. Further increase in the global burden of diabetes is predicted, reaching 592 million by 2035 \[[@CR5]\]. People with diabetes, compared to non-diabetic controls, were two- to three-fold more likely to develop TB \[[@CR6], [@CR7]\]. In 2013, an estimated 15% of adult cases of TB worldwide were attributed to diabetes, which corresponds to 1 million cases of diabetes-associated TB per year \[[@CR3]\]. Impaired immunity in diabetic patients is thought to contribute to the evolution of latent TB infection to active cases. Moreover, people with TB who have DM have a poorer response to treatment than do those without DM, and are therefore at a higher risk of TB treatment failure, death, and relapse after cure \[[@CR3], [@CR8]\]. Treatment failure in turn adds another significant challenge to the global TB control program, a drug-resistant TB \[[@CR1], [@CR9]\].

Multi-drug-resistant tuberculosis (MDR-TB), resistance to at least isoniazid and rifampicin, results from either primary infection with resistant bacteria or may develop in the course of a patient's treatment \[[@CR9]\]. In 2016, there were an estimated 600,000 incident cases of MDR-TB. In the same year, an estimated 4.1% of new cases and 19% of previously treated TB cases had MDR-TB \[[@CR1]\]. The emergence of multi-drug resistance across the world poses a global threat as the treatment is difficult, expensive, and a major healthcare cost burden to developing countries \[[@CR10]\]. Most cases of MDR-TB arise from a mixture of physician error, inadequate and incomplete treatment, and patient non-compliance during treatment of susceptible TB \[[@CR11], [@CR12]\]. Research reports also indicate that patients with MDR-TB and a co-morbidity of DM have a poor treatment response compared with non-diabetic MDR-TB controls \[[@CR13]\].

The additional risk of DM for the development of MDR-TB, however, remains controversial \[[@CR14]--[@CR16]\]. Many previous studies have found a 2.1 to 8.8 times increased risk of MDR-TB among TB patients co-morbid with diabetes \[[@CR17]--[@CR21]\]. In addition, observational studies from Israel, Georgia, and Mexico showed that TB patients with DM had a higher risk of developing MDR-TB \[[@CR22]--[@CR24]\]. In contrast, several others reported that there is no increased risk of MDR-TB among TB patients who have DM \[[@CR25]--[@CR28]\]. Similarly, none but one of the previously conducted systematic reviews and meta-analysis \[[@CR29]\] reported DM as an independent risk factor for MDR-TB. However, the pooled estimate in that study was based on limited number of studies which mostly implemented a cross-sectional or case-control study design. By conducting a comprehensive search until July 2018, we identified more studies and included six new cohort studies \[[@CR30]--[@CR35]\]. Therefore, with the present systematic review and meta-analysis, we aimed to assess the pooled effect estimate of DM on the development of MDR-TB with the careful inclusion of data from appropriately conducted observational studies.

Methods {#Sec2}
=======

Registration {#Sec3}
------------

Our systematic review has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (<http://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42016045692>). The protocol has been published elsewhere \[[@CR36]\]. This review is written in accordance with the recommendations from the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement guideline \[[@CR37], [@CR38]\], and a completed PRISMA checklist has been included (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Eligibility criteria {#Sec4}
--------------------

We included all observational studies (cross-sectional cohort, case-control cohort, and prospective and retrospective cohorts) which reported the association of DM and MDR-TB among TB patients. All eligible studies published in English and prior to July 30, 2018, were included for the review.

Data source and search strategy {#Sec5}
-------------------------------

PubMed, Excerpta Medica Database (EMBASE), Web of Science, and WHO Global Health Library databases were searched for all publications. We also searched cross-references of identified articles. In consultation with an experienced medical information specialist, a comprehensive search strategy has been developed (Table [1](#Tab1){ref-type="table"}). Search results were compiled using citation management software (RefWorks 2.0; ProQuest LLC, Bethesda, MD, USA, [http://www.refworks.com](http://www.refworks.com/)).Table 1Search strings used and number of identified abstracts per literature databaseComponentPubMedNo. of hitsEMBASENo. of hitsWeb of ScienceNo. of hitsWHO Global Health LibraryNo. of hitsDiabetes mellitus("Diabetes Mellitus" \[mesh\] OR diabetes\*\[tiab\] OR diabetic\*\[tiab\] OR T2DM \[tiab\] OR T1DM \[tiab\] OR "T2 DM"\[tiab\] OR "T1 DM"\[tiab\])612,633('Diabetes Mellitus'/exp. OR (diabetes\* OR diabetic\* OR T2DM OR T1DM OR 'T2 DM' OR 'T1 DM'): ab,ti)1,006,444TS = (diabetes\* OR diabetic\* OR T2DM OR T1DM OR "T2 DM" OR "T1 DM")649,798((Diabetes Mellitus) OR diabetes\* OR diabetic\* OR (T2DM) OR (T1DM) OR (T2 DM) OR (T1 DM))670,864Multi-drug-resistant tuberculosis("Tuberculosis, Multidrug-Resistant"\[Mesh\] OR\
(("Tuberculosis"\[Mesh\] OR tubercul\*\[tiab\] OR tb\[tiab\] OR antitubercul\*\[tiab\]) AND ("Drug Resistance, Multiple"\[Mesh\] OR multidrug resist\*\[tiab\] OR multi-drug resist\*\[tiab\] OR drug resist\*\[tiab\] OR MDR \[tiab\] OR multiresist\*\[tiab\] OR multi resist\*\[tiab\])) OR\
rifampcin resist\*\[tiab\] OR MDR-TB \[tiab\])16,247('Tuberculosis, Multidrug-Resistant'/exp. OR (('tuberculosis'/exp. OR (tubercul\* OR tb OR antitubercul\*): ab,ti) AND ('multidrug resistance'/exp. OR ('multidrug resist\*' OR 'drug resist\*' OR MDR OR multiresist\* OR 'multi resist\*'):ab,ti)) OR ('rifampcin resist\*' OR MDRTB):ab,ti)20,105TS = (tubercul\* OR tb OR antitubercul\*) AND TS = (multidrug resist\* OR drug resist\* OR MDR OR multiresist\* OR multi resist\* OR rifampcin resist\* OR MDRTB)17,917((Tuberculosis, Multidrug-Resistant) OR ((Tuberculosis) OR tubercul\* OR tb OR antitubercul\* AND (multidrug resist\* OR multi-drug resist\* OR drug resist\* OR MDR OR multiresist\* OR multi resist\*) OR\
rifampcin resist\* OR MDRTB))52,110Combined search\#1 AND \#2235\*\#1 AND \#2525\*\#1 AND \#2254\*\#1 AND \#2768\*\*Date of hits: July 30, 2018

Study selection {#Sec6}
---------------

Articles were screened and selected for full-text review if they met the following selection criteria: (1) provided or permitted the computation of an effect estimate of DM on the development of MDR-TB; (2) included TB patients (all type) and defined MDR-TB based on standard protocol; resistance at least to isoniazid and rifampicin \[[@CR9]\]; and (3) defined DM based on any of the following: baseline diagnosis by self-report, medical records, laboratory test, or treatment with oral hypoglycemic medications or insulin. We excluded studies for any of the following reasons: citations without abstracts, anonymous reports, duplicate studies, case reports, or studies which did not compare MDR-TB among people with DM to people without DM, and systematic reviews and meta-analysis. Additionally, studies that either did not provide effect estimates in odds ratios, rate ratios, hazard ratios, and relative risks or did not allow for the computation of these values were excluded. Two authors (BS and MM) screened and checked full-text studies for inclusion independently. Any disagreement was resolved by discussion. If consensus could not be reached, a third author determined the eligibility and approved the final list of retained studies.

Quality assessment and data extraction {#Sec7}
--------------------------------------

Meta-analysis of observational studies present particular challenges because of potential biases in the original studies and differences in study designs that make the calculation of a single summary estimate of effect of exposure potentially misleading \[[@CR39]\]. Thus, assessing quality of studies using a standardized tool helps to classify risk of bias which can help to explain variation in the results of included studies. Two authors (BS and MM) checked the quality of studies independently using Newcastle-Ottawa Scale (NOS) \[[@CR40]\] for cohort and case-control studies and the Agency for Healthcare Research and Quality (AHRQ) \[[@CR41]\] tool for cross-sectional studies as shown in Additional file [2](#MOESM2){ref-type="media"}: Table S2. Case-control and cohort studies qualified for inclusion if they scored 7 points or more from a total of 9 points in three domains of the equally weighted nine NOS components: selection (4 points), comparability (2 points), and exposure assessment (3 points). Cross-sectional studies were included in the analysis if they fulfilled all the four components (comparability, exposure, outcome measurement, and statistical analysis) of the AHRQ criteria. Structured data extraction form was constructed and pre-tested. For every study that met our eligibility criteria, two authors (BS and MM) independently extracted the title, name of authors, year of publication, country, study design, study population, sample size, data collection procedure, diagnosis of DM, and MDR-TB. Crude or adjusted effect sizes (ORs) with confidence intervals in the original studies were also extracted.

Statistical analysis {#Sec8}
--------------------

We estimated pooled OR with their 95% CI to evaluate the association between DM and MDR-TB among TB patients. Potential sources of heterogeneity between the studies were examined by using the Cochrane Q chi-squared statistic and *I*^2^ \[[@CR42], [@CR43]\], where *I*^2^ \> 75% suggested considerable heterogeneity. Presuming the variation of the true effect of DM on MDR-TB between studies, the random-effect model \[[@CR44]\] was fitted to estimate the summary effect (ORs) and 95% CIs across studies. Subgroup analyses were performed by study type, variable adjustment, DM type, and TB type and by the income level of the country where the primary study was conducted. Publication bias was assessed with the funnel plot for asymmetry, Egger's test, and Begger's regression models \[[@CR45]\]. To see the trend of evidence accumulation, we ran a cumulative meta-analysis. We conducted an influence analysis to observe the effect of omitting a single study on the overall pooled effect estimate \[[@CR46]\]. All analyses were performed using STATA SE 14.2 (Stata Corporation, College Station, TX) \[[@CR47]\]. All reported *P* values were two-sided at the level of 0.05.

Results {#Sec9}
=======

Search results {#Sec10}
--------------

We identified a total of 1782 studies based on the literature search in four databases including PubMed (235), EMBASE (525), Web of Science (254), and WHO Global Health library (768). Additionally, we found nine studies through a manual search (Fig. [1](#Fig1){ref-type="fig"}). After removal of duplicate studies, 1112 articles were screened based on titles and abstracts leaving 73 studies selected for a full-text review. Furthermore, 16 records were excluded from the full-text review (7 conference abstracts and correspondence/short communications and 9 full texts not accessible or available). Similarly, from the full-text review, we excluded 36 studies due to different reasons (6 were not written in English, 10 did not include comparisons, 17 did not define outcome clearly, and 3 had no enough outcome to estimate risks). List of the excluded articles after full-text review is available in Additional file [3](#MOESM3){ref-type="media"}. Finally, 21 articles were included for data synthesis. Additionally, three articles \[[@CR31], [@CR48], [@CR49]\] reported separate effect sizes for newly diagnosed and previously treated TB patients, and one study \[[@CR50]\] reported separate effect estimate by country (USA and Mexico), which resulted in a total of 25 studies or data points for analyses.Fig. 1Flow chart showing study selection process and search results

Study characteristics {#Sec11}
---------------------

Table [2](#Tab2){ref-type="table"} presents the characteristics of all the 25 studies \[[@CR14], [@CR18]--[@CR21], [@CR23], [@CR25], [@CR28], [@CR30]--[@CR35], [@CR48]--[@CR54]\] with a total sample of 13,403 participants with TB. The studies were published between 2001 and 2018 and covered different geographical regions: 13 studies were in Asia (three in China, three in Taiwan, two in Georgia, one in Bangladesh, one in Indonesia, one in Iran, one in Thailand, and one in South Korea), three studies were in Europe (one in Spain, one in Portugal, and one in Turkey), eight studies were in the Americas (four in Mexico, two in the USA, and two in Peru), and one study was in Africa (Egypt). From the total studies included in the analysis, nine were case-control \[[@CR18]--[@CR21], [@CR23], [@CR25], [@CR32], [@CR52], [@CR54]\], eight were cohort \[[@CR14], [@CR30], [@CR31], [@CR33]--[@CR35], [@CR53]\], and eight were cross-sectional \[[@CR28], [@CR48]--[@CR51]\] by study design. No adjustment for confounding was done in 12 of the included studies, while the remaining studies adjusted for at least one confounding factor. The most commonly adjusted factors were age, sex, smoking status, and HIV status (Table [2](#Tab2){ref-type="table"}). All the included studies passed quality assessment based on the Agency for Healthcare Research and Quality (AHRQ) \[[@CR41]\] tool for cross-sectional studies and Newcastle-Ottawa Scale (NOS) \[[@CR40]\] criteria for case-control and cohort studies (Additional file [2](#MOESM2){ref-type="media"}: Table S2).Table 2Characteristics of studies included in the meta-analysis assessing the association between diabetes mellitus and multi-drug-resistant tuberculosis AuthorCountyDesignSample size (TB-DM)Data collection procedureDM diagnosisDiagnosis of TBDiagnosis of MDR-TBTB typeDM typeOR (95% CI)^††^Adjustment to confoundersBaghaei P et al. \[[@CR25]\]IranCC282 (24)Record reviewNot specifiedNot specifiedNot specifiedAllType not mentioned0.68 (0.19--2.36)NoBashar M et al. \[[@CR18]\]USACC155 (50)Record reviewNot specifiedNot specifiedNot specifiedAllT1 and T25.30 (1.90--14.70)Homelessness and HIV statusCarreira S et al. \[[@CR34]\]PortugalRC246 (123)Record reviewFBS/previous history of DM and receiving insulin or oral hypoglycemic agentsNot specifiedNot specifiedAllType not mentioned1.49 (0.24--9.06)NoChang JT \[[@CR14]\]TaiwanPC192 (60)Record review/clinical/laboratoryFBSClinical/chest radiographs/sputum culture (LJ media)DST (proportional methods)NewT26.66 (0.68--65.38)NoFisher-Hoch SP et al. \[[@CR50]\]USACS1442 (401)Not mentionedSelf-reportSputum CultureDSTAllT22.14 (1.10--4.17)Age, gender, alcohol and drug abuse, HIV infection, history of previous TB infectionFisher-Hoch SP et al. \[[@CR50]\]^†^MexicoCS1436 (287)Not mentionedSelf-reportAFB/cultureDSTAllT21.80 (1.13--2.87)Age and genderGomez-Gomez A et al. \[[@CR23]\]MexicoCC175 (56)Record reviewFBS/HbA1cCulture/PCR for mycobacterium TB complexDST (proportion method)AllT1 and T22.51 (1.11--5.67)Age, sex, smoking history, chronic alcohol abuse, malnutrition, other illness conditionsHafez S et al. \[[@CR32]\]EgyptPC40 (12)Face-to-face interview/clinical/laboratoryFBSAFB/culture (LJ)DST (proportional method)AllT1 and T22.96 (0.73--11.93)NoHsu A et al. \[[@CR48]\]^\*^TaiwanCS139 (41)Record review/laboratoryFBSCultureDST (proportional method)Previously treatedT1 and T21.52 (0.59--3.95)Age, sexHsu A et al. \[[@CR48]\]TaiwanCS869 (204)Record review/labFBSCultureDST (proportional method)NewT1 and T20.95 (0.34--2.68)Age, sexJitmuang A et al. \[[@CR54]\]ThailandCC188 (31)Record reviewNot specifiedCulture (LJ)DST (proportional method)AllType not mentioned1.28 (0.54--3.02)NoMagee MJ et al. \[[@CR31]\]^\*^PeruPC823 (143)Record review/lab/interviewFBS/RBS/HbA1c/medication with Insulin or Oral hypoglycemic agentsAFBDST (Griess method)NewT1 and T20.45 (0.26--0.78)NoMagee MJ et al. \[[@CR53]\]GeorgiaPC263 (37)Face-to-face interview/clinical/labHbA1c¥AFB/culture (LJ)/X-rayDST (absolute concentration method)NewType not mentioned2.27 (1.02--5.08)Age, sex, HIV status and smokingMagee MJ et al. \[[@CR31]\]PeruPC848 (43)Record review/interview/labFBS/RBS/HbA1c/medication with Insulin or Oral hypoglycemic agentsAFBDST (Griess method)Previously treatedT1 and T21.10 (0.56--2.19)NoMi F et al. \[[@CR49]\]^\*^ChinaCS422 (144)Record reviewFBSAFB/culture (LJ-media)DST (proportional method)NewT21.3 (0.6--2.8)NoMi F et al. \[[@CR49]\]ChinaCS199 (43)Record reviewFBSAFB/culture (LJ-media)DST (proportional method)Previously treatedT20.5 (0.2--1.1)NoMin J et al. \[[@CR52]\]Korea, Rep.CC195 (55)Record reviewRecord reviewAFB/Chest radiographs/CultureDST (LJ-media)AllT1 and T22.68 (1.05--6.86)Age and smokingPerez-Navarro LM et al. \[[@CR19]\]MexicoCC409 (146)Record reviewFBSAFBNAAllT23.50 (1.10--11.10)AgePerez-Navarro LM et al. \[[@CR30]\]MexicoPC507 (183)Record review/self-report /labFBSAFBDST (BACTEC, MGIT)NewT23.50 (1.60--7.10)Age, sex, smoking, overcrowdingSaktiawati AMI et al. \[[@CR35]\]IndonesiaRC356 (23)Record reviewFBSAFB/positive chest X-ray/clinicalGeneXpert (MTB/RIF)/DSTAllT2Rifat M et al. \[[@CR20]\]BangladeshCC1000 (83)Face-to-face interview and record reviewNot specifiedAFB/X-rayPCR (Xpert MTB/RIF)/culture/DST/Line probe assayAllT22.56 (1.51--4.34)Age, education, occupation and smoking statusSalindri A et al. \[[@CR33]\]GeorgiaPC268 (36)Interview/labHbA1cMolecular diagnostic test/AFB/culture (LJ)/clinicalDST (absolute concentration method)NewType not mentioned2.51 (1.00--6.31)Age, sex, education, income, smoking status, alcohol use, HIV status, kidney diseaseSuarez-Garcia I et al. \[[@CR21]\]SpainCC696 (41)Record reviewNot specifiedCultureDST (agar proportion method)AllType not mentioned1.84 (0.53--6.33)NoTanrikulu A et al. \[[@CR28]\]TurkeyCC112 (9)Record reviewNot specifiedCultureDST (indirect proportion method)AllType not mentioned4.65 (1.01--21.51)NoZhang Q et al. \[[@CR51]\]ChinaCS2141 (203)Record reviewFBSAFB/sputum cultureDST (proportional method)AllT1 and T22.11 (1.42--3.11)No*T1* type I DM, *T2* type II, *DM* diabetes mellitus, *FBS* fasting blood sugar, *MDR-TB* multi-drug resistant tuberculosis, *TB* tuberculosis, *OR* odds ratio, *CI* confidence interval, *DST* drug susceptibility testing, *NA* not available, *FNAC* fine needle aspiration cytology, *PCR* polymerase chain reaction, *AFB* acid-fast bacilli, *PC* prospective cohort, *RC* retrospective cohort, *CC* case control, *CS* cross sectional, *LJ* Lowenstein Jensen, *HIV* human immunodeficiency virus, *TB-DM* refers to the number of TB patients co-morbid with DM in the sample^\*^These studies reported separate effect sizes for newly diagnosed and previously treated tuberculosis patients^†^This study reported separate effect sizes by country (USA and Mexico)^††^All effect sizes were presented as odd ratio

Associations between DM and MDR-TB {#Sec12}
----------------------------------

We explored the influence of each individual study on the overall meta-analysis summary estimate. Table [3](#Tab3){ref-type="table"} shows the influence of omitting a single study on the overall summary estimate. Accordingly, we identified that omitting Magee MJ et al. \[[@CR31]\] resulted in a large improvement on the overall summary estimate compared to the combined summary estimate obtained by omitting any one single study included in this meta-analysis (Table [3](#Tab3){ref-type="table"}). This study was then excluded from the rest of the analysis resulting in 24 observational studies considered to conduct this meta-analysis.Table 3Single study influence analysis on the overall meta-analysis summary estimate of the association between diabetes mellitus and multi-drug-resistant tuberculosisStudy omittedEffect size, OR95% CILCLUCLGomez-Gomez A et al. \[[@CR23]\]1.811.372.38Magee MJ et al. \[[@CR53]\]1.821.382.40Fisher-Hoch SP et al.^†^ \[[@CR50]\]1.841.382.45Hsu A et al.\* \[[@CR48]\]1.851.402.44Saktiawati AMI et al. \[[@CR35]\]1.751.362.26Rifat M et al. \[[@CR20]\]1.801.362.38Bashar M et al. \[[@CR18]\]1.761.352.29Perez-Navarro LM et al. \[[@CR30]\]1.771.352.33Fisher-Hoch SP et al. \[[@CR50]\]1.821.382.41Perez-Navarro LM et al. \[[@CR19]\]1.801.372.35Salindri AD et al. \[[@CR33]\]1.811.382.38Min J et al. \[[@CR52]\]1.811.372.38Hsu A et al. \[[@CR48]\]1.881.432.46Chang JT \[[@CR14]\]1.831.382.42Zhang Q et al. \[[@CR51]\]1.821.372.43Hafez S et al. \[[@CR32]\]1.811.382.38Magee MJ et al.\* \[[@CR31]\]1.881.432.48Jitmuang A et al. \[[@CR54]\]1.861.412.46Mi F et al.\* \[[@CR49]\]1.931.492.49Suarez-Garcia I et al. \[[@CR21]\]1.831.402.41Magee MJ et al. \[[@CR31]\]1.971.582.45Baghaei P et al. \[[@CR25]\]1.881.442.46Tanrikulu A et al. \[[@CR28]\]1.791.372.35Mi F et al. \[[@CR49]\]1.871.412.46Carreira S et al. \[[@CR34]\]1.841.402.41Combined1.831.402.39*UCL* upper confidence limit, *LCL* lower confidence limit, *CI* confidence interval, *OR* odds ratio\*These studies reported separate effect sizes for newly diagnosed and previously treated tuberculosis patients^†^This study reported separate effect sizes by country (USA and Mexico)

Based on the meta-analysis of 24 observational studies, the overall pooled effect estimate was 1.97 (OR = 1.97, 95% CI 1.58 to 2.45, *I*^2^ = 38.2%, *P* value for heterogeneity = 0.031). This result indicated a 97% increased risk of MDR-TB among TB-DM co-morbid patients. The significant and positively increased risk of MDR-TB among TB-DM co-morbid patients remained in the same direction in a subgroup analysis by study characteristics. When seen by level of adjustment to a confounding factor, studies which adjusted for at least one confounding factor had more than a two-fold increased risk of MDR-TB (OR = 2.43, 95% CI 1.90 to 3.12) (Fig. [2](#Fig2){ref-type="fig"}). In a subgroup analysis of studies which adjusted for a minimum of one confounding factor, a strong positive association was observed by study design (cross-sectional, 4 studies, OR = 1.72, 95% CI 1.23 to 2.41; case-control, 5 studies, OR = 2.89, 95% CI 2.02 to 4.12; cohort, 4 studies, OR = 3.36, 95% CI 1.82 to 6.20) and method of TB diagnosis (culture confirmed, 8 studies, OR = 1.97, 95% CI 1.51 to 2.57; Sputum smear test, 5 studies, OR = 3.73 95% CI 2.33 to 5.97) (Table [4](#Tab4){ref-type="table"}).Fig. 2Forest plot showing the results of random effects meta-analysis of 24 observational studies. The horizontal line and vertical dotted line in the middle indicate the 95% confidence interval and its corresponding odds ratio (OR) estimateTable 4Subgroup analyses of 24 observational studies on the association between diabetes mellitus and multi-drug-resistant-tuberculosis among tuberculosis patients co-morbid with diabetes mellitusStudy characteristicsStudies that adjusted for at least one covariateStudies that did not adjustment for covariatesNo. of studiesPooled OR (95% CI)*I*^2^ (%)*P* value^¥^No. of studiesPooled OR (95% CI)*I*^2^ (%)*P* value^¥^Study design Case control52.89 (2.02, 4.12)0.00.77341.39 (0.79, 2.45)0.00.459 Cohort43.36 (1.82, 6.20)40.20.17131.47 (0.93, 2.34)0.00.501 Cross sectional41.72 (1.23, 2,41)19.10.25041.45 (0.68, 3.09)73.20.011Type of TB Both or not defined72.72 (1.88, 3.94)38.40.13671.90 (1.40, 2.60)0.00.492 New52.36 (1.59, 3.51)3.80.38521.64 (0.99, 2.71)0.00.436 Previously treated1^†^20.77 (0.36, 1.67)35.40.115Diagnosis of TB Culture confirmed81.97 (1.51, 2.57)0.00.83181.60 (1.08, 2.38)43.60.088 Sputum smear test only53.73 (2.33, 5.97)28.00.23531.03 (0.58, 182)0.00.736Type of DM Type 262.67 (1.82, 3.93)40.70.13431.12 (0.52, 2.42)67.30.047 Type 1 and type 252.22 (1.31, 3.76)35.80.18331.77 (1.08, 2.89)35.50.212 Not defined22.37 (1.29, 4.34)0.00.87251.46 (0.84, 2.51)0.00.428Diagnosis of DM HbA1c or FBS32.42 (1.49, 3.93)0.00.9811^†^ Only FBS62.68 (1.45, 4.96)53.50.05661.50 (0.93, 2.42)51.60.066 Self-report/unspecified42.33 (1.65, 3.29)21.50.28241.49 (0.77, 2.89)21.90.279Country income level\* Lower middle income42.95 (1.69, 5.16)40.60.1681^†^ Upper middle income42.32 (1.65, 3.28)0.00.41871.27 (0.80, 2.01)56.90.031 High income52.13 (1.29, 3.52)34.60.19131.88 (1.07, 3.29)0.00.963 Overall132.43 (1.90, 3.12)19.10.250111.45 (1.05, 2.02)35.40.115*OR* odds ratio, *I*^*2*^ the variation in estimate attributable to heterogeneity, ¥ *P* value for heterogeneity, *CI* confidence interval, *TB* tuberculosis, *DM* diabetes mellitus, *FBS* fasting blood sugar, *HbA1c* glycosylated hemoglobin^†^Effect estimate not pooled due limited number of available studies\*Income level based on World Bank Classification ([*https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups*](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups))

To evaluate consistency of the evidence over the years along with its sufficiency, we ran a cumulative meta-analysis which calculates effect estimates as newer studies are added. Accordingly, between 2001 and 2014, there was a positive association between DM and MDR-TB but with a swinging effect size. However, with the addition of three case-control and four cohort studies between 2014 and 2018, a strong evidence that TB patients co-morbid with DM had an increased risk of developing MDR-TB has sustained (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Cumulative forest plot showing the results of random effects meta-analysis for the 24 observational studies on the association of DM and MDR-TB. The first row shows the effect based on one study, the second row shows the cumulative effect based on two studies, and so on

There was no significant publication bias found either by the Egger's regression asymmetry test or by a funnel plot (Fig. [4](#Fig4){ref-type="fig"}a). The contour-enhanced funnel plot examination (Fig. [4](#Fig4){ref-type="fig"}b) confirms this, which distinguished between publication bias and other causes. It showed that small studies were found not only in the areas of statistical significance but also in areas of non-statistical significance.Fig. 4Funnel plot **a** and contour-enhanced funnel plot **b** of the included observational studies. In the contour-enhanced plot, the shaded region indicates areas of statistical significance, and non-statistical significance is represented in white. The vertical line corresponds to the summary log (OR) as estimated from the random-effect model (OR, odds ratio)

Discussion {#Sec13}
==========

In this study, we pooled estimates on the association between DM and MDR-TB from 24 observational studies and identified a significant and positive association with a low between-study heterogeneity. In a pooled estimate of studies which adjusted for at least one confounding factor, stronger association was observed by study design, type of TB, method of TB diagnosis, type of DM, method of DM diagnosis, and country income level.

The pooled effect estimate, in subgroup analyses of 13 studies which adjusted for at least one confounding factor, on the association between DM and MDR-TB (OR = 2.43, 95% CI 1.90 to 3.12, *I*^2^ = 19.1%, *P* value = 0.250) was consistent in the direction of association, but stronger than what was reported in a previous systematic review and meta-analysis (OR = 1.71, 95% CI 1.32 to 2.22, *I*^2^ = 46.8%, *P* value = 0.020) \[[@CR29]\]. This difference could be due to the fact that Liu et al. \[[@CR29]\] mixed three studies which reported unadjusted OR \[[@CR21], [@CR49], [@CR54]\], while we included three new cohort studies that reported adjusted OR \[[@CR30], [@CR33], [@CR35]\]. Compared to a similar prior meta-analysis \[[@CR29]\], we included 10 additional studies \[[@CR14], [@CR25], [@CR28], [@CR30]--[@CR35], [@CR51]\] and supplemented this with strong analytical rigor. Thus, our meta-analysis fortifies the evidence base for the association between DM and MDR-TB. Our results are also in agreement with a review that showed TB and DM co-morbidity were more likely to be evident among people with anti-TB drug resistance \[[@CR55]\], signifying a clear association between the two diseases. In another review, Baker et al. \[[@CR8]\] did not find an increased risk of MDR-TB among people with DM. However, it is worth mentioning that this study aimed to review literature on the impact of DM on TB outcomes, and this particular sub-analysis included only four studies. Although not having MDR-TB as an outcome, another review noted significant associations in the pooled risk of association between DM and active TB without regarding the type of study design implemented \[[@CR56]\].

Signifying a stability of association, we found a significant and positive association between DM and MDR-TB in subgroup analyses of studies which adjusted for at least one confounding factor. The association persisted irrespective of the country where the primary studies were conducted which covered diverse population groups, how DM or TB diagnosis was made, and study design of the primary studies. However, pooled estimate of a weaker strength was found in studies which did not adjust for at least one confounding factor (OR = 1.45, 95% CI 1.05 to 2.02). We included studies which reported unadjusted effect estimate to reduce inflation of the pooled effect estimate from the adjusted only analysis, increase the number of available studies for analysis, and widen the representativeness of our findings \[[@CR57]\]. Although unadjusted findings lack adjustment by statistical methods, they attempted to adjust at the design level albeit still suffering from an unobserved confounding effect. Therefore, we suggest our findings should be interpreted with caution.

In subgroup analyses of studies which adjusted for at least one confounding factor on the association between DM and MDR-TB, there was an increased risk in lower middle-income countries (OR = 2.95, 95% CI 1.69 to 5.16) compared to that found in upper middle-income countries (OR = 2.32, 95% CI 1.65 to 3.28) and high-income countries (OR = 2.13, 95% CI 1.29 to 3.52). This might be due to more studies in high-income- or upper middle-income country settings diagnosed DM by blood test (FBS or HbA1c) or confirmed TB diagnosis based on culture which may have reduced bias due to misclassification \[[@CR19], [@CR23], [@CR30], [@CR48], [@CR50], [@CR52]\]. Consistent with our finding that there was an increased risk of MDR-TB among TB-DM co-morbid patients in lower middle-income countries, a meta-analysis by Al-Rifai et al. \[[@CR56]\] reported that there was a higher risk of TB-DM association in lower middle-income countries compared to high-and upper middle-income countries.

A strong association was found in subgroup analyses by TB type in studies which reported adjusted estimate, where DM increased the risk of MDR-TB among new TB patients (OR = 2.36, 95% CI 1.59 to 3.51) and in those with undefined TB type (OR = 2.72, 95% CI 1.88 to 3.94). However, due to inadequate number of studies which adjusted for at least one confounding factor and included only previously treated TB patients, we did not present a pooled estimate on the risk of MDR-TB among previously treated TB-DM co-morbid patients. Therefore, we are not able to confirm whether DM is indeed not a risk factor for MDR-TB among previously treated TB patients. The meta-analysis by Liu et al. \[[@CR29]\] also reported similar findings on the risk of any MDR-TB (OR = 1.94, 95% CI 1.42 to 2.65) and primary MDR-TB (OR = 1.69, 95% CI 1.09 to 2.62) among TB patients co-morbid with DM. Due to the addition of three cohort studies \[[@CR30], [@CR33], [@CR35]\], which were not included in the Liu et al.'s meta-analysis \[[@CR29]\], we reported a stronger pooled effect estimate for the increase in the risk of MDR-TB among new- and any-TB patients co-morbid with DM. Similarly, irrespective of the study design used in the primary studies which adjusted for at least one confounding factor, we consistently found a significant and positive association between DM and MDR-TB in cross-sectional (OR = 1.72 95% CI 1.23 to 2.41), case-control (OR = 2.89, 95% 2.02 to 4.12), and cohort studies (OR = 3.36, 95% CI 1.82, 6.20). Similar findings were reported by Liu et al. for case-control studies but not for cross-sectional studies \[[@CR29]\]. Because only one cohort study was included \[[@CR53]\] by Liu et al. \[[@CR29]\], we cannot compare the pooled estimate from cohort studies in our meta-analysis to theirs. Though it is difficult to establish causality based on evidence from observational studies, we believe that these pooled estimates from studies which controlled for potential confounding factors further solidify the existence of a strong association between DM and MDR-TB among patients co-morbid with TB.

In this study, we have shown the most substantial evidence to date on the association between DM and MDR-TB by including a comprehensive list of studies carried out in various settings around the world. Methodologically, we conducted a cumulative meta-analysis to see the trend of evidence and performed a single study influence analysis and subgroup analysis. However, we would also like to acknowledge potential limitations of this study. Firstly, we have not included studies published in non-English languages. Given majority of MDR-TB cases and co-morbidities are from Russia, China, and India \[[@CR1]\], exclusion of studies from these countries might bias our finding. Secondly, the inclusion of studies which did not consistently define the type of TB and did not control for potential confounding factors increased the observed heterogeneity among studies. However, in an attempt to deal with this, we have performed and reported sensitivity analysis. Finally, potential misclassification regarding a non-uniform diagnosis of DM and TB among participants included in the different studies might have contributed to varying risk estimates. This is particularly observed in the stratified analysis based on diagnosis of DM and TB, where higher estimates were observed for those diagnosed based on information obtained from medical records and self-reports, (diagnosis of DM: FBS from medical record, OR = 2.68, 95% CI 1.45 to 4.96; HbA1c, OR = 2.42, 95% CI 1.49 to 3.93; self-report, OR = 2.33,, 95% CI 1.65 to 3.29) and (diagnosis of TB: culture confirmed, OR = 1.97, 95% CI 1.51 o 2.57; AFB only from medical record, OR = 3.73, 95% CI 2.33 to 5.97).

In conclusion, our results demonstrate that a more robust TB treatment and follow-up might be necessary for patients with DM. In light of the global DM epidemic \[[@CR5]\], this study emphasizes the message that there is a strong need for a bi-directional screening and co-management approach in the attempt to halt the TB-DM co-morbidity \[[@CR58]\]. Even though countries representing diverse income levels were not included in our study, we stress the need to maximize efforts to prevent DM and TB co-morbidity and reduce the burden of MDR-TB in countries with varying economical standings. The integrated and collaborative effort between TB and DM control programs will ultimately count on achieving the global "*End TB Strategy*" \[[@CR2]\]. Efforts to control DM can have a substantial beneficial effect on TB outcomes, particularly in the case of MDR-TB. Policymakers can focus on new targets pertaining to an enhanced care plan for DM patients with TB, particularly among the slightest evidence of problems with adherence or prolonged and complicated infections. Furthermore, focus on the early identification and treatment of individuals with the co-morbidity can result in an enhanced treatment outcome. We recommend future prospective cohort studies to focus on bacteriologically confirmed TB cases that objectively diagnose DM, with clearly defined types of both TB and DM coupled with robust controls for potential confounding.
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AFB

:   Acid-fast bacilli

CI

:   Confidence interval

DM

:   Diabetes mellitus

DST
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FBS

:   Fasting blood sugar
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:   Fine needle aspiration
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MDR-TB

:   Multi-drug-resistant tuberculosis
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